Arena Pharmaceuticals Inc: (NASD: ARNA)
$7.51
0.01 (0.13%)
Volume 5,392,820
Jun 18 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 7.40 - 7.57 |
| 52wk Low - High | 6.95 - 13.50 |
| Previous Close | 7.50 |
| Avg. Volume | 5,541,080 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 1.63 B |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.18 |
| P/E (F1) | 0.00 |
| Current Year Est. | -0.12 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
105 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| P/E (F1) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.12 |
| Current Quarter Estimate | 0.12 |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 08-08-2013 |
| EPS Last Year | -0.38 |
| Expected Earnings Growth | NA |
Company Description
Arena Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena's most advanced product candidate, lorcaserin, is being investigated in a Phase three clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | 0.12 | -0.05 | -0.12 | -0.24 |
| Number of Estimates | 6 | 5 | 7 | 6 |
| Low Estimate | -0.11 | -0.12 | -0.15 | -0.39 |
| High Estimate | 0.19 | 0.17 | -0.08 | NA |
| Year Ago EPS | -0.12 | -0.07 | -0.42 | -0.12 |
| EPS Growth | 202.78% | 22.86% | 72.11% | -104.88% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| ARENA PHARMA | ARNA | 7.50 | |
|
| AETERNA ZENTARS | AEZS | 1.90 | |
|
| BIOGEN IDEC INC | BIIB | 207.75 | |
|
| MYRIAD GENETICS | MYGN | 26.62 | |
|
| PROTALIX BIOTHR | PLX | 5.04 | |
|
| ADDEX THERA LTD | ADDXF | 3.95 | |
|
| AFFYMAX INC | AFFY | 1.09 | |
|
| ALEXION PHARMA | ALXN | 91.32 | |
|
| ALNYLAM PHARMA | ALNY | 29.69 | |
|
| ANTHERA PHARMA | ANTH | 0.57 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Zacks Commentary
ARNA Sheds Light on Belviq Launch
May 09, 2013
VIVUS Reports Wider Loss
May 09, 2013
Arena Pharma Narrows Loss
May 06, 2013
The Zacks Analyst Blog Highlights: Microsoft, VIVUS, Arena Pharmaceuticals, Orexigen Therapeutics and UCB
Apr 19, 2013
Expanded Access for VIVUS' Qsymia
Apr 18, 2013
Patients Dosed in Arena Study
Apr 09, 2013
ARNA/Eisai's Belviq Filed in Mexico
Apr 03, 2013
Vivus Opts for Royalty Financing
Apr 02, 2013
Financials
| EPS TTM | -0.38 |
| Sales | 28 |
| Net Income | -78 |
| Price/Earnings | NA |
| Price/Book | 20.28 |
| Price/Cash Flow | NA |
| Price/Sales | 58.81 |
News
Arena Pharmaceuticals to Present at the 2013 Wells Fargo Securities Healthcare Conference - Close-Up Media
Jun 19, 2013
Arena Pharmaceuticals announces launch of obesity drug in US - Datamonitor
Jun 18, 2013
Consumer Reports Says "Exercise" Rather Than Take This Drug - TheMotleyFool
Jun 17, 2013
Five Star Equities Issues New Research Reports on ARNA, DD, KR and VECO - Accesswire
Jun 17, 2013
Myriad Genetics had the Lowest Relative Performance in the Biotechnology Industry (MYGN, ARNA, EXAS, IMGN, VRTX) - Financial News Network Online - News Corner
Jun 17, 2013
Shares of Arena Pharmaceuticals Under Pressure, Down 2.5% - Financial News Network Online - Market Movers
Jun 17, 2013
The Top 5 Diseases Caused by Obesity - TheMotleyFool
Jun 16, 2013
Arena Pharmaceuticals to Present at the 2013 Wells Fargo Securities Healthcare Conference - Pr Newswire
Jun 14, 2013
Broker Recommendations
| Current ABR | 2.50 |
| ABR (Last Week) | 2.50 |
| # of recs in ABR | 10 |
| Average Target Price | 9.50 |
| Industry Rank by ABR | 105 out of 265 |
| Rank in Industry | 31 out of 153 |
